A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderately to Severely Active Crohns Disease

Interventions

DRUG: Afimkibart
DRUG: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]